Don’t Buy Viatris And Organon Just Because Of The Dividends (NYSE:OGN)
RichVintage Introduction As my regular readers know, I was originally very positive about the prospects of Viatris Inc. (NASDAQ:VTRS), even after the announced sale of its Biosimilars division (see my February and May 2022 articles). […]
